Page last updated: 2024-11-11

licarin b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

licarin B: neolignan; RN given for (2S-(2alpha,3beta,5(E)))-isomer; isolated from seeds of Myristica fragrans; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6441061
CHEMBL ID259386
SCHEMBL ID12604783
MeSH IDM0305321

Synonyms (18)

Synonym
51020-87-2
licarin b
CHEMBL259386 ,
licarine b
bdbm50303148
(+)-licarin b
1,3-benzodioxole, 5-((2r,3r)-2,3-dihydro-7-methoxy-3-methyl-5-(1e)-1-propenyl-2-benzofuranyl)-
nsc 370990
SCHEMBL12604783
licarinb
AC-34420
Q-100947
AKOS030632872
BS-16929
5-((2r,3r)-7-methoxy-3-methyl-5-((e)-prop-1-en-1-yl)-2,3-dihydrobenzofuran-2-yl)benzo[d][1,3]dioxole
HY-N0479
CS-0009000
DTXSID601317642
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Prostaglandin G/H synthase 1Ovis aries (sheep)IC50 (µMol)289.00000.00032.177410.0000AID443489
Prostaglandin G/H synthase 2Ovis aries (sheep)IC50 (µMol)52.10000.00101.453910.0000AID443490
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID443492Selectivity ratio of IC50 for ovine COX-1 to IC50 for ovine COX-22009Bioorganic & medicinal chemistry letters, Dec-15, Volume: 19, Issue:24
COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans.
AID323984Proliferative effect in human MCF7 BUS cells assessed as ratio of increase in cell number in drug treated to control2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Structure and estrogenic activity of new lignans from Iryanthera lancifolia.
AID443489Inhibition of ovine COX-1 assessed as inhibition of transformation of AA to PGH2 by EIA2009Bioorganic & medicinal chemistry letters, Dec-15, Volume: 19, Issue:24
COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans.
AID443493Antiplatelet activity in rabbit platelets assessed as inhibition of platelet activating factor-induced platelet aggregation2009Bioorganic & medicinal chemistry letters, Dec-15, Volume: 19, Issue:24
COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans.
AID323985Proliferative effect in human MCF7 BUS cells assessed as increase in cell number relative to 17-beta estradiol2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Structure and estrogenic activity of new lignans from Iryanthera lancifolia.
AID443491Inhibition of potato LOX-5 assessed as inhibition of hydroperoxide production after 5 mins by EIA2009Bioorganic & medicinal chemistry letters, Dec-15, Volume: 19, Issue:24
COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans.
AID443494Antiplatelet activity in rabbit platelets assessed as inhibition of arachidonic acid-induced platelet aggregation2009Bioorganic & medicinal chemistry letters, Dec-15, Volume: 19, Issue:24
COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans.
AID443490Inhibition of ovine COX-2 assessed as inhibition of transformation of AA to PGH2 by EIA2009Bioorganic & medicinal chemistry letters, Dec-15, Volume: 19, Issue:24
COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans.
AID443495Antiplatelet activity in rabbit platelets assessed as inhibition of adenosin 5'-diphosphate-induced platelet aggregation2009Bioorganic & medicinal chemistry letters, Dec-15, Volume: 19, Issue:24
COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans.
AID323986Proliferative potency in human MCF7 BUS cells assessed as induction of maximal cell proliferation relative to 17-beta estradiol2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Structure and estrogenic activity of new lignans from Iryanthera lancifolia.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's2 (33.33)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.45 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.77 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.45)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]